Analysis of adverse events with ruxolitinib using real-world datasets and drug-interaction networks
This retrospective analysis using the Japanese Adverse Drug Event Report database indicated potential associations between ruxolitinib and adverse events, including anemia and bacterial infections. Future research should explore the underlying pharmacological mechanisms using functional enrichment analysis of ruxolitinib-associated genes related to blood toxicity and bacterial infections.
Authors
- Hirofumi Tamaki (ORCID: https://orcid.org/0000-0002-4543-1176)
- Moe Yamashita
- Ryogo Umetsu
- Mizuki Tanaka (ORCID: https://orcid.org/0000-0002-6302-323X)
- Mika Maezawa (ORCID: https://orcid.org/0000-0002-9166-1351)
- Kohei Shiota (ORCID: https://orcid.org/0000-0001-9650-6003)
- Mitsuhiro Nakamura (ORCID: https://orcid.org/0000-0002-5062-5522)
- Kazuhiro Iguchi (ORCID: https://orcid.org/0000-0003-1506-9804)
- Tomofumi Yamazaki
- Koumi Miyasaka
- Yuka Nokura
- Satoshi Nakao (ORCID: https://orcid.org/0000-0001-7413-2637)
- Hideyuki Tanaka
- Sakiko Hirofuji
- Nanaka Ichihara
- Kana Sugishita
Institutions
- Gifu Pharmaceutical University (JP)
- Kyushu University Hospital (JP)
Publication Details
- Journal
- SAGE Open Medicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1177/20503121251348420
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science